Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a needed cuppa stimulation. Our choice today is ginger peach turmeric. Meanwhile, here is the latest menu of tidbits to help you on your way. We hope you conquer the world and have a wonderful day. And as always, please do stay in touch. We appreciate feedback, tips, and criticism. … The Trump administration is pulling the nomination of Heidi Overton to lead the U.S. Food and Drug Administration over concerns that she lacked support to get confirmed by the Senate, STAT notes. The Senate’s health panel had been expected to vote on her nomination Wednesday, and the panel’s leader, Sen. Bill Cassidy (R-La.), said on Tuesday that Overton had enough support to clear his committee and win confirmation. But some GOP lawmakers had reservations about Overton, a preventive care doctor who served in the Trump White House, due to her support for scaling back vaccine recommendations, her role in loosening restrictions on vapes, and her stance on abortion policy. Merck plans to stop development of its experimental blood cancer drug, nemtabrutinib, after a review found the benefits may not outweigh the risks, Reuters says. An independent monitoring committee reached that conclusion after reviewing results from a late-stage study and Merck said its review of the full data confirmed the finding. The decision ends a broader development program for treating chronic lymphocytic leukemia and small lymphocytic lymphoma, including two other late-stage trials. Nemtabrutinib is an oral drug designed to block BTK, a protein that helps cancerous B cells grow. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe
STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.